Pathophysiological basis for the application of noradrenergic transmission blockade in the therapy of cerebral ischemic accidents.
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001923:Brain Chemistry / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D002395:Catecholamines / Q000378:metabolism; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000503:physiopathology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D006801:Humans; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D051381:Rats; D013565:Sympatholytics / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D002395:Catecholamines; D013565:Sympatholytics; D009638:Norepinephrine